NSAID-induced upper gastrointestinal (GI) damage occurs easily in people with a prior history of complicated or uncomplicated ulcers. Many recent clinical studies have proved the benefit of Helicobacter pylori eradication in NSAID users; however, the exact pathophysiologic relationship between concomitant H. pylori infection and NSAID use has not yet been fully elucidated. Testing and eradication of H. pylori are generally recommended in patients who are at a high risk for NSAID-induced GI damage. However, in high-risk patients, ulcer prophylaxis with proton pump inhibitor or misoprostol is needed even if H. pylori has been successfully eradicated. In low-risk patients, it is still questionable whether or not eradication of H. pylori can reduce upper GI damage. However, in western countries, due to its cost effectiveness, testing and eradication of H. pylori is recommended before starting aspirin or NSAID irrespective of the risk level. In regions with a high prevalence of H. pylori infection (＞20%), the usefulness of testing and eradication of H. pylori has not yet been determined. (Korean J Gastroenterol 2014;64:70-75) 
INTRODUCTION
NSAIDs and aspirin are prescribed worldwide. Upper gastrointestinal (GI) damage due to these drugs has been the main concern and its complication such as bleeding is a life-threatening condition. The risk of NSAID-induced upper GI damage is increased in the elderly, Helicobacter pylori infection, concomitant corticosteroid and anticoagulant use, and prior history of ulcers. 
MAIN SUBJECTS

Pathophysiology
H. pylori and NSAIDs are the most important risk factors in the pathogenesis of gastric mucosal damage. Some studies have shown that the interaction between H. pylori and NSAIDs in ulcer development may be independent, synergistic, additive, or antagonistic. 2 In general, the harmful ef- 12 patients with no prior history of ulcers also showed a reduction in the occurrence of ulcers after H. pylori eradication.
They also reported that both H. pylori eradication and PPI were equally effective in reducing the risk of ulcer in naïve NSAID users. 12 However, this is quite controversial, with conflicting results in patients who are already receiving NSAIDs.
The meta-analysis by Vergara et al. 13 showed that eradication seems less effective than treatment with a maintenance PPI 
Clinical studies of H. pylori eradication in aspirin users
Like NSAIDs, aspirin can also cause upper GI damage.
Low-dose aspirin (75-325 mg) is widely used for prevention of cardiovascular or cerebrovascular events in at-risk patients. Even low-dose aspirin is an important predisposing factor for peptic ulcer bleeding and intestinal injuries such as small bowel bleeding. 18 Although the mechanism of ulceration is complex, it appears that reduced production of COX-generated cytoprotective prostaglandins induces ulceration. The risk of bleeding is also increased because of plate- A systematic review of the impact of H. pylori on upper GI bleeding risk in aspirin users indicated that the current data are not sufficient to allow a meta-analysis or to draw firm conclusions. 19 In a case control study by Lanas et al., 20 H. pylori infection was found to be an independent risk factor for ulcer bleeding in patients taking low-dose aspirin (OR, 4.7; 95% CI, 2.0-10.9). One study showed that eradication of H.
pylori is equivalent to treatment with omeprazole in prevention of recurrent ulcer bleeding in aspirin users. 19 Among patients taking aspirin, the probability of recurrent bleeding during the six-month period was 1.9% for those who received eradication therapy and 0.9% for those who received omeprazole (absolute difference, 1.0%; 95% CI, −1.9-3.9).
18
In a large-scale, long-term, prospective cohort study, the incidence of ulcer bleeding (per 100 patient-years) in the H. 
